WASHINGTON - US biotech firm Moderna said Wednesday that doses of its new COVID-19 vaccine candidate aimed at the South African coronavirus variant had been shipped to the US National Institutes of Health for testing.
That means people who were infected with the classic strain are more susceptible to reinfection, and research has also shown the variant has partly reduced the protection of the current generation of vaccines. Another idea is that people could receive a third dose of the classic vaccine to raise their overall immunity.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:
Ey, we have a chance in 2022!